The represents of Shanghai De Novo Pharmatech Co., Ltd participated in the annual meeting of the American Association for Cancer Research (AACR) in 2018 and did Poster exhibition in this annual meeting.

· 2018 AACR Abstract 5555: Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancer.

· 2018 AACR Abstract 3772: Preclinical study of a novel TLR8 selective agonist for cancer immunotherapy.

American Association for Cancer Research (AACR) was founded in 1907, and it is the oldest and largest scientific organization focused on cancer research in the world.  AACR attracts researchers in the field relying on its scientific breadth and excellent reputation, and promotes the exchange of new knowledge and new ideas between the scientists in the field.